Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Research conducted at P. Hersey and co-authors has provided new information about melanoma
July 29th, 2008
According to a study from Newcastle, Australia, " In the present study, we have examined whether treatment of patients with metastatic melanoma with matured dendritic cell (DC) vaccines with or without low dose IL-2 may improve treatment outcomes. Sixteen patients received DC vaccines (DCs) sensitized with autologous melanoma lysates and 18 patients received DCs sensitized with peptides from gp100, MART-1, tyrosinase, MAGE-3.A2, MAGE-A10 and NA17." "IL-2 was given subcutaneously (sc) at 1 MU/m(2) on the second day after each injection for 5-14 days in half of each group. DCs were given by intranodal injection. There were 2 partial responses (PR) and 3 with stable...
Source: Cancer Weekly (2008-07-29)
|
